Top

Research Article

Split Viewer

Mol. Cells 2011; 32(6): 543-548

Published online December 31, 2011

https://doi.org/10.1007/s10059-011-0160-1

© The Korean Society for Molecular and Cellular Biology

Selection and Optimization of Asymmetric siRNA Targeting the Human c-MET Gene

Seul-gi Jo1,3, Sun Woo Hong1,2,3, Jae Wook Yoo1, Chang Han Lee1, Sera Kim1, Soyoun Kim2, and Dong-ki Lee1,*

1Global Research Laboratory for RNAi Medicine, Department of Chemistry and Brain Korea 21 School of Chemical Materials Science, Sungkyunkwan University, Suwon 440-746, Korea, 2Department of Biomedical Engineering, Dongguk University, Seoul 100-715, Korea, 3These authors contributed equally to this work.

Correspondence to : *Correspondence: dklee@skku.edu

Received: August 1, 2011; Revised: September 15, 2011; Accepted: September 19, 2011

Abstract

The silencing of specific oncogenes via RNA interference (RNAi) holds great promise for the future of cancer therapy. RNAi is commonly carried out using small interfering RNA (siRNA) composed of a 19 bp duplex region with a 2-nucleotide overhang at each 3’ end. This classical siRNA structure, however, can trigger non-specific effects, which has hampered the development of specific and safe RNAi therapeutics. Previously, we developed a novel siRNA structure, called asymmetric shorter-duplex siRNA (asiRNA), which did not cause the non-specific effects triggered by conventional siRNA, such as off-target gene silencing mediated by the sense strand. In this study, we first screened potent asiRNA molecules targeting the human c-MET gene, a promising anticancer target. Next, the activity of a selected asiRNA was further optimized by introducing a locked nucleic acid (LNA) to maximize the gene silencing potency. The optimized asiRNA targeted to c-MET may have potential as a specific and safe anticancer RNAi therapeutic.

Keywords asiRNA, cancer, c-MET, RNA interference, siRNA

Article

Research Article

Mol. Cells 2011; 32(6): 543-548

Published online December 31, 2011 https://doi.org/10.1007/s10059-011-0160-1

Copyright © The Korean Society for Molecular and Cellular Biology.

Selection and Optimization of Asymmetric siRNA Targeting the Human c-MET Gene

Seul-gi Jo1,3, Sun Woo Hong1,2,3, Jae Wook Yoo1, Chang Han Lee1, Sera Kim1, Soyoun Kim2, and Dong-ki Lee1,*

1Global Research Laboratory for RNAi Medicine, Department of Chemistry and Brain Korea 21 School of Chemical Materials Science, Sungkyunkwan University, Suwon 440-746, Korea, 2Department of Biomedical Engineering, Dongguk University, Seoul 100-715, Korea, 3These authors contributed equally to this work.

Correspondence to:*Correspondence: dklee@skku.edu

Received: August 1, 2011; Revised: September 15, 2011; Accepted: September 19, 2011

Abstract

The silencing of specific oncogenes via RNA interference (RNAi) holds great promise for the future of cancer therapy. RNAi is commonly carried out using small interfering RNA (siRNA) composed of a 19 bp duplex region with a 2-nucleotide overhang at each 3’ end. This classical siRNA structure, however, can trigger non-specific effects, which has hampered the development of specific and safe RNAi therapeutics. Previously, we developed a novel siRNA structure, called asymmetric shorter-duplex siRNA (asiRNA), which did not cause the non-specific effects triggered by conventional siRNA, such as off-target gene silencing mediated by the sense strand. In this study, we first screened potent asiRNA molecules targeting the human c-MET gene, a promising anticancer target. Next, the activity of a selected asiRNA was further optimized by introducing a locked nucleic acid (LNA) to maximize the gene silencing potency. The optimized asiRNA targeted to c-MET may have potential as a specific and safe anticancer RNAi therapeutic.

Keywords: asiRNA, cancer, c-MET, RNA interference, siRNA

Mol. Cells
Aug 31, 2022 Vol.45 No.8, pp. 513~602
COVER PICTURE
Cryo-EM structure of human porphyrin transporter ABCB6 (main figure) shows that binding of hemin (inset, magenta) in concert with two glutathione molecules (cyan) primes ABCB6 for high ATP turnover (Kim et al., pp. 575-587).

Supplementary File

Share this article on

  • line
  • mail

Related articles in Mol. Cells

Molecules and Cells

eISSN 0219-1032
qr-code Download